The $165M immunology startup Sheila Gujrathi bet on after Receptos, Gossamer is shooting for an IPO
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Sheila Gujrathi has kept herself busy since leaving the helm of Gossamer Bio in the aftermath of a mid-stage flop. She signed on to a few biotech boards, most recently to become Ventyx Bio’s executive chair.
But it turns out her connection with the biotech runs much deeper. As Ventyx revealed in its S-1, Gujrathi made a small investment in the company during the Series A — which took place between February and June 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.